The new 44,000 sq ft facility encompasses office and laboratory space and is equipped to support future enhancements in the fields of early biology and natural product drug discovery.
Thomas D’Ambra, president and CEO of AMRI, said: “In this current business climate, we believe the pharmaceutical industry will continue to be challenged to simultaneously contain costs while continuing to populate new drug pipelines, resulting in an increased demand for outsourcing services.”